Other molecules have been investigated in the microenvironment of HLs, such as lymphocyte-activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin-domain containing proteins 3 (TIM-3) and it was demonstrated that in all cases of HLs there is immune-expression of these pathways, that could be targeted in future clinical trials, particularly, in cases of relapsed/refractory HL. Here, LAG3 is linked to Hydrolethalus.